FDA Inspection 1196909 — AmbioPharm, Inc
The FDA completed an inspection of AmbioPharm, Inc on February 9, 2023 in Beech Island, SC. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- February 9, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Beech Island, SC (United States)